Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan

BACKGROUND: Real-world clinical experience with afatinib as a treatment for advanced lung adenocarcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations (G719X, L861Q and S768I) has rarely been reported. OBJECTIVE: We aimed to perform a retrospective multicenter study to analyze...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Ping-Chih, Lee, Suey-Haur, Chiu, Li-Chung, Lee, Chung-Shu, Wu, Chiao-En, Kuo, Scott Chih-Hsi, Ju, Jia-Shiuan, Huang, Allen Chung-Cheng, Li, Shih-Hong, Ko, Ho-Wen, Yang, Cheng-Ta, Wang, Chin-Chou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042759/
https://www.ncbi.nlm.nih.gov/pubmed/36805452
http://dx.doi.org/10.1007/s11523-023-00946-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042759/
https://www.ncbi.nlm.nih.gov/pubmed/36805452
http://dx.doi.org/10.1007/s11523-023-00946-w

Ejemplares similares